Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

NovaMed Raises $14 Million to In-license New Molecules

publication date: Jan 22, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NovaMed Pharmaceuticals Inc., a CRO and out-sourced distribution company based in Shanghai, announced that it has closed a Series B funding round worth $13.8 million. In May 2007, the company raised $5 million in an A round. NovaMed was founded in 2005. NovaMed said that it would use the money to in-license new molecules to develop in China, expand its sales/distribution organization and build up its R&D capacity. More details...

Stock Symbols: (NYSE: WX) (NYSE: SNY) (NYSE: BAX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners